

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10587804	
	Filing Date		2007-06-07	
	First Named Inventor	Bouquin, T.		
	Art Unit			
	Examiner Name			
	Attorney Docket Number		0279us310	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	20030124555	A1	2003-07-03	Brasch, et al.		
	2	20040106118	A1	2004-06-03	Kolmar, et al.		
	3	20020086427	A1	2002-07-04	Leiden, et al.		

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1162270	EP	A2	2001-12-12	SCRIPPS RESEARCH INST		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10587804
Filing Date		2007-06-07
First Named Inventor	Bouquin, T.	
Art Unit		
Examiner Name		
Attorney Docket Number	0279us310	

2	1477808	EP	A1	2004-11-17	PROBIOGEN AG		<input type="checkbox"/>
3	2002034906	WO	A2	2002-05-02	GEORG AUGUST UNI GOETTINGEN		<input type="checkbox"/>
4	2003014361	WO	A1	2003-02-20	ALTANA PHARMA AG		<input type="checkbox"/>
5	2003099996	WO	A2	2003-12-04	Biogen, Inc.		<input type="checkbox"/>
6	2001044516	WO	A2	2001-06-21	Tularik Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Abo T., et al. SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells 7(7):629-638, 2002.	<input type="checkbox"/>
	2	Arner E.S.J., et al. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J. Mol. Biol. 292(5):1003-1016, 1999.	<input type="checkbox"/>
	3	Bedwell D.M., et al.. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nature Med. 3:1280-1284, 1997.	<input type="checkbox"/>
	4	Barton-Davis E.R., et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104:375-381, 1999.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10587804
Filing Date	2007-06-07
First Named Inventor	Bouquin, T.
Art Unit	
Examiner Name	
Attorney Docket Number	0279us310

5	Burke J.F and Mogg, A.E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13 (17):6265-6272, 1985.	<input type="checkbox"/>
6	Chang C.C., et al. Evolution of a cytokine using DNA family shuffling. Nat. Biotechnol. 17(8):793-797, 1999.	<input type="checkbox"/>
7	Gorman C.M., et al. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11 (21):7631-7648, 1983.	<input type="checkbox"/>
8	Howard M., et al. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 2:467-469, 1996.	<input type="checkbox"/>
9	Hunt L., et al. Fluorescent proteins in animal cells for process development:optimization of sodium butyrate treatment as an example. Biotechnol. Bioeng. 77(5):528-537, 2002.	<input type="checkbox"/>
10	Ikezawa, H. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol. Pharm. Bull. 25 (4):409-417, 2002.	<input type="checkbox"/>
11	Kawagishi J., et al. Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 30 (2):224-232, 1995.	<input type="checkbox"/>
12	Kozak, M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196(4):947-950, 1987.	<input type="checkbox"/>
13	Kurtzman A., et al. Advances in directed protein evolution by recursive genetic recombination:applications to therapeutic proteins. Curr. Opin. Biotechnol. 12(4):361-370, 2001.	<input type="checkbox"/>
14	Manuvakhova M., et al. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6(7):1044-1055, 2000.	<input type="checkbox"/>
15	Millan, J.L. Molecular cloning and sequence analysis of human placental alkaline phosphatase. J. Biol. Chem. 261 (7):3112-3115, 1986.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10587804
Filing Date	2007-06-07
First Named Inventor	Bouquin, T.
Art Unit	
Examiner Name	
Attorney Docket Number	0279us310

16	Pack P., et al. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246:28-34, 1995.	<input type="checkbox"/>
17	Pack P., et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnol. 11 :1271-1277, 1993.	<input type="checkbox"/>
18	Pack P., and Plueckthun, A. Miniantibodies:use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31:1579-1584, 1992	<input type="checkbox"/>
19	Palmer E., et al. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 277 (5692):148-150, 1979.	<input type="checkbox"/>
20	Stansfield I., et al. The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in Saccharomyces cerevisiae. EMBO J. 14:4365-4373, 1995.	<input type="checkbox"/>
21	Whalen R., et al. DNA shuffling and vaccines. Curr. Opin. Mol. Ther. 3 (1):31-36, 2001.	<input type="checkbox"/>
22	Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (6941):762-769, 2003.	<input type="checkbox"/>
23	Zhouravleva G., et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 14(16):4065-4072, 1995.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Teresa Wessendorf/	Date Considered	9/13/10
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.